COMMUNIQUÉS West-GlobeNewswire

Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
20/07/2026
Vancouver, Canada, July 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (“ Clearmind ”) (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogen - derived treatments for [...]
DLH to Announce Fiscal 2026 Third Quarter Financial Results
20/07/2026
ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital [...]
Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
20/07/2026
New headquarters reflects Collegium's long-term vision and commitment to Massachusetts STOUGHTON, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) a leading biopharmaceutical [...]
University of Szeged Pioneers First Robotic Cardiology Program in Hungary
20/07/2026
First Robotic Magnetic Navigation system installed in Hungary University of Szeged, led by Cardiology Chief Dr. Szili-Torok, expected to treat hundreds of patients annually with all forms of cardiac arrhythmia using [...]
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
20/07/2026
Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemotherapy in stage 4 non- [...]
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
20/07/2026
- Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER [...]
Positron Secures Multiple PET-CT Orders Amid Accelerating Shift to Cardiac PET
20/07/2026
BUFFALO, NY, July 20, 2026 (GLOBE NEWSWIRE) -- Positron Corporation ("Positron" or the "Company") (OTC: POSC), a leader in advanced molecular imaging technology and comprehensive PET imaging solutions, today announced [...]
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
20/07/2026
Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third Fast Track [...]
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
20/07/2026
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease type 1, having met the primary efficacy endpoint, reduction in lesion growth Presentation to include positive update [...]
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
20/07/2026
Highlights combined company’s strong financial position with over $900 million expected at closing, Treeline’s deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expected new program [...]
Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry
20/07/2026
Ongoing Xanamem (emestedastat) Alzheimer’s disease pivotal trial progresses toward final results in November this year SYDNEY, July 20, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces that [...]
Vireo Growth Inc. to Acquire Certain Assets of The Cannabist Company Holdings Inc.
20/07/2026
Enters definitive agreement that expands its operations in one market and enters four additional states MINNEAPOLIS, July 20, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “ [...]
Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar
20/07/2026
MELBOURNE, Australia, July 20, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Kalkine Media Webinar on [...]
Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.
20/07/2026
REDWOOD CITY, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the Special Committee of Seer’s Board of [...]
Nouscom Selected for Oral Presentation on NOUS-209 Re-treatment and Long-Term Follow-Up in Lynch Syndrome Carriers at ESMO Congress 2026
20/07/2026
New data from the Phase 1b/2 trial of NOUS-209 in Lynch Syndrome (LS) carriers have been accepted for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 NOUS-209 is an off-the-shelf [...]
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
20/07/2026
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply. Company Expresses Support for MHRA Draft Rare Disease Therapies [...]
ColestZen Official Launch 2026 - Natural Cholesterol Support Supplement for Adults (US, UK, Canada, and Australia)
20/07/2026
The ColestZen Official Store has introduced ColestZen, a dietary supplement formulated with ingredients selected to support healthy cholesterol levels, help maintain blood sugar levels already within the normal range, [...]
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
20/07/2026
Scientific Advice from the German Regulatory Authority supports the biological rationale and proposed development approach for VERAXA's BiTAC-TCE technology and product candidate, providing an initial de-risking of the [...]
Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
20/07/2026
REHOVOT, Israel and HOBOKEN, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious [...]

Pages